Enveric Biosciences, Inc. (ENVB) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -422.69%.
Criteria proven by this page:
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -459.3 | -18.89 | 109.54 | 35.34 | - |
| 2017 | -76.9 | -0.42 | 35.87 | 14.35 | 299.52% |
| 2018 | -3.7 | -0.21 | 5.78 | 1.45 | 3,361,132.67% |
| 2019 | -32.0 | 0.34 | 16.87 | 4.49 | - |
| 2020 | -53.6 | 0.73 | 107.63 | 0.00 | - |
| 2021 | -6.7 | -0.08 | 14.77 | 0.00 | - |
| 2022 | -4.3 | 0.05 | 5.37 | 0.00 | - |
| 2023 | -2,850.4 | -267.13 | 25.19 | 0.00 | - |
| 2024 | -0.3 | 0.00 | 1.70 | 0.00 | - |
| 2025 | -0.1 | 0.00 | 0.29 | 0.00 | 276.49% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1,064.17 | $36.15M | $-2.78M | -7.7% |
| 2017 | $-3,028.98 | $48.59M | $-9.07M | -18.7% |
| 2018 | $-3,551.39 | $43M | $-16.9M | -39.3% |
| 2019 | $-211.99 | $39.91M | $-5.6M | -14% |
| 2020 | $-55.50 | $0.00 | $-6.39M | - |
| 2021 | $-103.69 | $0.00 | $-48.98M | - |
| 2022 | $-13.00 | $0.00 | $-18.47M | - |
| 2023 | $-8.09 | $0.00 | $-17.29K | - |
| 2024 | $-19.04 | $0.00 | $-9.57M | - |
| 2025 | $-36.24 | $0.00 | $-12.13M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-315.00 | $-315.00 – $-315.00 | $10M | $10M – $10M | 1 |
| 2027 | $-111.60 | $-111.60 – $-111.60 | $15M | $15M – $15M | 1 |
| 2028 | $-43.20 | $-43.20 – $-43.20 | $25M | $25M – $25M | 1 |
